Literature DB >> 31719131

Survival bias explains improved survival in smokers and hypertensive individuals after aSAH.

Joni V Lindbohm1, Jaakko Kaprio2, Miikka Korja2.   

Abstract

OBJECTIVE: Two recent hospital-based studies have reported that both smoking and hypertension-the 2 most important risk factors for aneurysmal subarachnoid hemorrhage (aSAH)-may improve survival after aSAH. We tested the hypothesis that a higher case fatality among smokers and hypertensive individuals after aSAH contributes to these paradoxical findings.
METHODS: We followed 65,521 population-based FINRISK participants during 1.52 million person-years and identified 445 first-ever hospitalized aSAHs and 98 sudden-death aSAHs occurring between 1974 and 2014. We measured risk factors prior to disease onset in the cohort surveys, and confirmed, among all sudden-death aSAHs, 80% by extensive (including the brain) forensic autopsy; the remaining 20% were based on clinical examination (CT of the head, spinal tap, or both). The Cox proportional hazards model estimated survival curves.
RESULTS: Analyses repeating the protocol of the 2 recent hospital-based studies again showed improved survival among smokers and those with hypertension. Conversely, in analyses including more accurate risk factor measurements and including patients with sudden-death aSAH who never reached a hospital, these paradoxical results were reversed. Smokers had reduced survival compared to that of never-smokers (p = 0.04), and those with high systolic blood pressure (SBP) (≥160 mm Hg) had reduced survival when compared to survival of those with SBP <160 mm Hg (p = 0.05).
CONCLUSIONS: After aSAH, smoking and hypertension were associated with worse survival. The earlier and opposite findings are likely explained by inadequate risk factor measurement and by survival bias inherent to hospital-based risk factor studies lacking information on out-of-hospital deaths confirmed by autopsy.
© 2019 American Academy of Neurology.

Entities:  

Year:  2019        PMID: 31719131     DOI: 10.1212/WNL.0000000000008537

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Impact of smoking on course and outcome of aneurysmal subarachnoid hemorrhage.

Authors:  H Slettebø; T Karic; A Sorteberg
Journal:  Acta Neurochir (Wien)       Date:  2020-07-30       Impact factor: 2.216

2.  Neurointensive care results and risk factors for unfavorable outcome in aneurysmatic SAH: a comparison of two age groups.

Authors:  Teemu Luostarinen; Jarno Satopää; Vilja Välimäki; Rahul Raj; Jyri J Virta
Journal:  Acta Neurochir (Wien)       Date:  2021-01-29       Impact factor: 2.216

3.  Body Mass Index and the Risk of Poor Outcome in Surgically Treated Patients With Good-Grade Aneurysmal Subarachnoid Hemorrhage.

Authors:  Ilari Rautalin; Seppo Juvela; R Loch Macdonald; Miikka Korja
Journal:  Neurosurgery       Date:  2022-03-24       Impact factor: 5.315

4.  Mortality among patients treated for aneurysmal subarachnoid hemorrhage in Eastern Denmark 2017-2019.

Authors:  Agnes T Stauning; Frank Eriksson; Goetz Benndorf; Anders V Holst; John Hauerberg; Trine Stavngaard; Lars Poulsgaard; Per Rochat; Vagn Eskesen; Peter Birkeland; Tiit Mathiesen; Tina N Munch
Journal:  Acta Neurochir (Wien)       Date:  2022-07-22       Impact factor: 2.816

5.  Nicotine Replacement Therapy for Smokers with Acute Aneurysmal Subarachnoid Hemorrhage: An International Survey.

Authors:  Christian V Eisenring; Preci L Hamilton; Bawarjan Schatlo; David Nanchen; Philippe Herzog; Markus F Oertel; Isabelle Jacot-Sadowski; Felice Burn; Jacques Cornuz
Journal:  Adv Ther       Date:  2022-09-19       Impact factor: 4.070

6.  Risk factors associated with albuminuria in Rwanda: results from a STEPS survey.

Authors:  Candide Tran Ngoc; Prebo Barango; Roger Harrison; Andrew Jones; Steven Velabo Shongwe; Albert Tuyishime; François Uwinkindi; Hongyi Xu; Stephanie Shoop-Worrall
Journal:  BMC Nephrol       Date:  2021-11-01       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.